Pura Vida Investments LLC Sells 424,120 Shares of Outset Medical, Inc. $OM

Pura Vida Investments LLC decreased its position in shares of Outset Medical, Inc. (NASDAQ:OM) by 98.8% in the third quarter, Holdings Channel.com reports. The firm owned 5,000 shares of the company’s stock after selling 424,120 shares during the period. Outset Medical comprises 0.5% of Pura Vida Investments LLC’s holdings, making the stock its 8th largest holding. Pura Vida Investments LLC’s holdings in Outset Medical were worth $71,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Legal & General Group Plc acquired a new position in Outset Medical in the 2nd quarter worth about $34,000. Ameritas Investment Partners Inc. acquired a new stake in shares of Outset Medical during the 2nd quarter valued at about $35,000. BNP Paribas Financial Markets grew its stake in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after buying an additional 2,034 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new position in Outset Medical in the second quarter worth approximately $78,000. Finally, New York State Common Retirement Fund acquired a new stake in Outset Medical in the second quarter valued at approximately $108,000.

Analyst Ratings Changes

Several research firms have commented on OM. Weiss Ratings reissued a “sell (e+)” rating on shares of Outset Medical in a research report on Monday, December 29th. BTIG Research decreased their price objective on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, February 12th. Stifel Nicolaus lowered their target price on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 7th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $7.00 price target on shares of Outset Medical in a research report on Wednesday, December 17th. Finally, Wall Street Zen downgraded Outset Medical from a “hold” rating to a “sell” rating in a research note on Sunday, February 8th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Outset Medical currently has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Activity

In related news, EVP Marc Nash sold 5,375 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total transaction of $27,520.00. Following the completion of the sale, the executive vice president owned 42,785 shares in the company, valued at $219,059.20. This represents a 11.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Leslie Trigg sold 11,794 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $5.12, for a total value of $60,385.28. Following the completion of the sale, the chief executive officer directly owned 107,823 shares in the company, valued at $552,053.76. This trade represents a 9.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 40,910 shares of company stock valued at $193,040. 2.40% of the stock is owned by insiders.

Outset Medical Stock Performance

NASDAQ:OM opened at $3.53 on Thursday. The firm has a market capitalization of $64.63 million, a PE ratio of -0.52 and a beta of 2.12. Outset Medical, Inc. has a 1 year low of $3.10 and a 1 year high of $21.98. The company has a current ratio of 6.67, a quick ratio of 5.40 and a debt-to-equity ratio of 0.76. The firm’s fifty day simple moving average is $4.30 and its 200 day simple moving average is $8.42.

Outset Medical Profile

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.